The UK and US have signed a important bilateral deal that will ensure zero duties on British drug exports being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the public health system. This move secures that import taxes on these crucial exports will stay at zero for a duration of 36 months.
This agreement follows previous warnings to hike duties on patented pharmaceutical imports, with potential rates discussed reaching one hundred percent.
"This deal between the Britain bolsters the worldwide climate for cutting-edge drugs and introduces much-needed fairness to American-British pharmaceutical trade," a statement noted.
Trade Importance
Pharmaceuticals constitute one of the Britain's most significant export categories to the US, which is by far the primary buyer for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to last September, the UK exported medicines worth billions to the US. This figure represented 17.4% of British export trade in that span.
"This guarantee protects jobs, boosts investment and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement includes several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to raise total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments exceeded 20%.
Broader Context
The pact takes place against a protracted dispute between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were intensified by arguments that US customers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its resources over the past decade.
